Related Experiment Video
Updated: Aug 14, 2025
08:52
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
8.2K
Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage
Tiziana Scarnà1, Marion Menozzi-Arnaud1, Martin Friede2
1Gavi, the Vaccine Alliance, Geneva, Switzerland.
Expert Opinion on Drug Delivery
|January 17, 2023
Summary
Investment in vaccine microarray patches (vMAPs) manufacturing is crucial for rapid development and global access. Scaling up vMAP production can enhance epidemic preparedness and vaccine delivery worldwide.
Area of Science:
- Vaccinology
- Biotechnology
- Public Health
Background:
- Vaccine microarray patches (vMAPs) offer a transformative approach to vaccine deployment.
- Global health initiatives require scalable and accessible vaccine solutions.
Purpose of the Study:
- To highlight the critical need for investment in vMAP manufacturing capabilities.
- To emphasize the potential of vMAPs in improving epidemic preparedness and global vaccine access, particularly in low- and lower-middle-income countries (LMICs).
Main Methods:
- Review of lessons learned from pandemic responses.
- Analysis of the requirements for pilot manufacturing and scale-up.
- Discussion of incentive mechanisms for manufacturing investment.
Main Results:
- vMAPs have the potential to revolutionize vaccine deployment and reach.
- Investment in manufacturing-at-risk can accelerate vMAP development and approval.
- Pilot manufacturing is essential for clinical trials and emergency response.
Conclusions:
- Strategic investment in vMAP manufacturing is essential for future pandemic preparedness.
- Parallel scaling of manufacturing with clinical studies can expedite vMAP availability.
- Incentives are necessary to de-risk early investment in vMAP production facilities.
